Search - tctmd.com

Displaying 361 - 380 of 422

Sort: Relevancy | Date

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

News Daily News

Endovascular Therapy for DVT Appears Safe, Effective in Registries

January 22, 2013

News Daily News

PLATO Substudy: Ticagrelor Advantage Persists After First Ischemic Event

January 07, 2013

News Daily News

TCTMD’s Top 10 Most Popular News Stories for 2012

Jason Kahn

January 02, 2013

News Industry News

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

October 25, 2012

News Conference News TCT 2012

Presentations Examine Multiple Facets of Antiplatelet Agents

October 24, 2012

News Conference News TCT 2012

Mesh-Covered Stent Shines in MASTER Trial

October 24, 2012

News Daily News

Meta-analysis Looks at Novel Anticoagulants Plus Dual Therapy in ACS Patients

October 02, 2012

News Daily News

PLATO Substudy: Ticagrelor Associated with Less Bleeding, Infection, Death than Clopidogrel after CABG

September 27, 2012

News Conference News ESC 2012

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Caitlin E. Cox

September 04, 2012

News Conference News ESC 2012

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

Caitlin E. Cox

August 27, 2012

News Conference News ESC 2012

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

August 26, 2012

News Daily News

Reversible Anticoagulation Shows Promise for ACS Patients Undergoing Catheterization

August 14, 2012

News Daily News

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Jason Kahn

June 22, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

News Industry News

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

May 23, 2012

News Conference News EuroPCR 2012

Strong Showing for Bioabsorbable-Scaffold DES

Caitlin E. Cox

May 16, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

News Daily News

Residual Syntax Score Predicts Outcome After Incomplete Revascularization

L.A. McKeown

April 10, 2012

News Daily News

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

April 10, 2012

Advertisement

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Endovascular Therapy for DVT Appears Safe, Effective in Registries

PLATO Substudy: Ticagrelor Advantage Persists After First Ischemic Event

TCTMD’s Top 10 Most Popular News Stories for 2012

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

Presentations Examine Multiple Facets of Antiplatelet Agents

Mesh-Covered Stent Shines in MASTER Trial

Meta-analysis Looks at Novel Anticoagulants Plus Dual Therapy in ACS Patients

PLATO Substudy: Ticagrelor Associated with Less Bleeding, Infection, Death than Clopidogrel after CABG

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Low-Dose Rivaroxaban Curbs Thrombotic Events in STEMI Patients

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

Reversible Anticoagulation Shows Promise for ACS Patients Undergoing Catheterization

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Strong Showing for Bioabsorbable-Scaffold DES

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Residual Syntax Score Predicts Outcome After Incomplete Revascularization

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content